Which Diabetes Drugs Cross the Blood-Brain Barrier Best? Tirzepatide Leads
Tirzepatide showed the highest rate of blood-brain barrier crossing among four incretin drugs tested in mice, suggesting the strongest potential for direct brain effects.
Quick Facts
What This Study Found
Tirzepatide had the highest rate of blood-brain barrier crossing among the four incretin receptor agonists tested, suggesting it may be the most promising for direct brain effects.
Key Numbers
Four drugs tested: albiglutide, dulaglutide, DA5-CH, and tirzepatide. Adult male CD-1 mice were used with radioactive labeling (125I or 14C).
How They Did This
Researchers injected adult male mice with radioactively labeled versions of four drugs and measured brain uptake using multiple-time regression analysis.
Why This Research Matters
If incretin drugs can cross the blood-brain barrier, they might directly protect brain cells in diseases like Alzheimer's and Parkinson's. Knowing which drugs cross best helps prioritize which ones to study further.
The Bigger Picture
Multiple incretin drugs show promise for neurodegenerative diseases. Knowing which ones actually reach the brain helps prioritize which should advance to clinical trials for Alzheimer's and Parkinson's.
What This Study Doesn't Tell Us
This was an animal study in mice, so brain uptake rates may differ in humans. The study measured how much drug reaches the brain but did not test whether it produces therapeutic effects there.
Questions This Raises
- ?Does higher brain uptake translate to greater neuroprotection?
- ?Would the same ranking hold in humans with different blood-brain barrier properties?
Trust & Context
- Key Stat:
- Tirzepatide: highest brain uptake Among four incretin receptor agonists, tirzepatide showed the greatest ability to cross the blood-brain barrier in mice
- Evidence Grade:
- Rated preliminary: pharmacokinetic study measuring brain uptake in mice, but does not test whether brain exposure translates to therapeutic effects.
- Study Age:
- Published in 2024. Part of growing interest in repurposing diabetes drugs for neurodegenerative diseases.
- Original Title:
- Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.
- Published In:
- Tissue barriers, 12(4), 2292461 (2024)
- Authors:
- Rhea, Elizabeth M(2), Babin, Alice, Thomas, Peter, Omer, Mohamed, Weaver, Riley, Hansen, Kim, Banks, William A, Talbot, Konrad
- Database ID:
- RPEP-09144
Evidence Hierarchy
Frequently Asked Questions
Could diabetes drugs treat Alzheimer's?
Some show promise in animal studies, and tirzepatide's ability to reach the brain makes it a leading candidate for further investigation.
Why does brain entry matter?
A drug needs to physically reach the brain to directly protect neurons. Many promising drugs fail because they can't cross the blood-brain barrier.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09144APA
Rhea, Elizabeth M; Babin, Alice; Thomas, Peter; Omer, Mohamed; Weaver, Riley; Hansen, Kim; Banks, William A; Talbot, Konrad. (2024). Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.. Tissue barriers, 12(4), 2292461. https://doi.org/10.1080/21688370.2023.2292461
MLA
Rhea, Elizabeth M, et al. "Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.." Tissue barriers, 2024. https://doi.org/10.1080/21688370.2023.2292461
RethinkPeptides
RethinkPeptides Research Database. "Brain uptake pharmacokinetics of albiglutide, dulaglutide, t..." RPEP-09144. Retrieved from https://rethinkpeptides.com/research/rhea-2024-brain-uptake-pharmacokinetics-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.